OTCMAPNHY
Market cap4.22bUSD
Dec 20, Last price
9.38USD
1D
-2.42%
1Q
-14.09%
Jan 2017
-53.74%
Name
Aspen Pharmacare Holdings Ltd
Chart & Performance
Profile
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anesthetics, muscle relaxants, and topical agents under the Anaesthetics brand; and a range of injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand. It also offers branded consumer, prescription, and over-the-counter products under the regional brands, such as Circadin, Foxair, Maltofer, Mybulen, and Zyloric for various types of anesthetic comprises sleeping aid, respiratory, iron supplement, analgesic, and uric acid production inhibitor. In addition, the company manufactures and sells active pharmaceutical ingredients and finished dose form products to third-party customers. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.
Valuation
Title ZAR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | 2015‑06 | |
Income | ||||||||||
Revenues | 44,706,000 9.82% | 40,709,000 5.45% | 38,606,000 2.22% | |||||||
Cost of revenue | 35,552,000 | 27,114,000 | 25,129,000 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 9,154,000 | 13,595,000 | 13,477,000 | |||||||
NOPBT Margin | 20.48% | 33.40% | 34.91% | |||||||
Operating Taxes | 1,310,000 | 1,327,000 | 1,646,000 | |||||||
Tax Rate | 14.31% | 9.76% | 12.21% | |||||||
NOPAT | 7,844,000 | 12,268,000 | 11,831,000 | |||||||
Net income | 4,404,000 -15.76% | 5,228,000 -19.42% | 6,488,000 35.00% | |||||||
Dividends | (1,525,000) | (1,455,000) | (1,196,000) | |||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | (56,000) | (136,000) | 15,661,000 | |||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 11,314,000 | 7,907,000 | 11,665,000 | |||||||
Long-term debt | 25,737,000 | 21,647,000 | 10,927,000 | |||||||
Deferred revenue | 1,177,000 | 10,000 | ||||||||
Other long-term liabilities | 3,191,000 | 353,000 | 4,480,000 | |||||||
Net debt | 24,060,000 | 18,377,000 | 16,058,000 | |||||||
Cash flow | ||||||||||
Cash from operating activities | 6,225,000 | 5,520,000 | 5,374,000 | |||||||
CAPEX | (5,535,000) | (3,181,000) | (2,697,000) | |||||||
Cash from investing activities | (9,468,000) | (3,421,000) | (2,161,000) | |||||||
Cash from financing activities | 3,623,000 | (420,000) | (4,676,000) | |||||||
FCF | 4,780,000 | 7,896,000 | 16,638,000 | |||||||
Balance | ||||||||||
Cash | 12,337,000 | 10,912,000 | 6,183,000 | |||||||
Long term investments | 654,000 | 265,000 | 351,000 | |||||||
Excess cash | 10,755,700 | 9,141,550 | 4,603,700 | |||||||
Stockholders' equity | 85,225,000 | 86,584,000 | 127,300,000 | |||||||
Invested Capital | 113,751,300 | 106,496,450 | 91,015,300 | |||||||
ROIC | 7.12% | 12.42% | 13.28% | |||||||
ROCE | 7.26% | 11.56% | 13.81% | |||||||
EV | ||||||||||
Common stock shares outstanding | 444,200 | 444,200 | 453,000 | |||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | 11,127,000 | 15,383,000 | 15,190,000 | |||||||
EV/EBITDA | ||||||||||
Interest | 2,227,000 | 1,324,000 | 765,000 | |||||||
Interest/NOPBT | 24.33% | 9.74% | 5.68% |